CME Presentations

CIDP


Presentations


Speakers

  • Peter D. Donofrio, MD

    Peter D. Donofrio, MD

    Peter D. Donofrio, MD

    Professor of Neurology

    Peter D. Donofrio, MD, is a professor of neurology, director of the Division of Neuromuscular Disorders, head of the Muscular Dystrophy Association Clinic, the ALS Clinic, and director of the EMG Lab at Vanderbilt University Medical Center in Nashville, Tennessee. His active research interests are polyneuropathy, GBS, CIDP, and motor neuron disorders. Dr Donofrio holds special interest in ALS, myasthenia gravis and peripheral neuropathy, in drug research and clinical trials of medications that could potentially slow the progression of ALS, and in medications that may improve the function of patients with myasthenia gravis. He earned his medical degree from The Ohio State University and completed a neurology residency and fellowship at the University of Michigan.
  • Betsy Blake, PharmD, BCPS, FNAP

    Betsy Blake, PharmD, BCPS, FNAP

    Betsy Blake, PharmD, BCPS, FNAP

    Director of Interprofessional Education, Department of Clinical Pharmacy and Outcomes Sciences

    Betsy Blake, PharmD, BCPS, FNAP, is director of Interprofessional Education and a clinical associate professor in the Department of Clinical Pharmacy and Outcomes Sciences at the University of South Carolina College of Pharmacy in Columbia. She was diagnosed with Guillain Barre Syndrome (GBS) initially in January 2015, but her diagnosis was changed to CIDP after persistent relapses. Throughout Betsy’s disease course, she has been treated with many medications and therapies and still receives regular infusions of IVIG. She serves as a liaison for the GBS-CIDP Foundation International to provide support to patients with GBS and CIDP. Betsy’s experience as a CIDP patient has enhanced her professional skills working with students and patients to improve health outcomes.

CME Information

CIDP: Improving Timely Diagnosis, Assessment, and Treatment


Global Logo PQH Logo

LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:
  • Formulate a differential-diagnosis strategy for a patient presenting with symptoms suggestive of CIDP
  • Identify a treatment plan using current therapeutic options, including coordination of multidisciplinary care and provision of supportive treatment
  • Summarize data from ongoing clinical trials with agents targeting the IgG neonatal Fc receptor
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, working in collaboration with the GBS|CIDP Foundation International.

ACKNOWLEDGEMENT

This activity is supported by educational grants from argenx US, Inc. and Grifols.

DATE OF RELEASE/EXPIRATION

Thursday, August 5, 2021 from 11:30am – 12:30pm ET

TARGET AUDIENCE

The educational design of this activity addresses the needs of neurologists, neuromuscular specialists, immunologists, primary care providers, hospitalists, emergency physicians, advanced practitioners, nurses, and pharmacists involved in the treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

STATEMENT OF NEED/PROGRAM OVERVIEW

While CIDP is the most common of the acquired immune-mediated demyelinating neuropathies, it remains a challenge to differentiate it from other immune-mediated inflammatory conditions. Clinicians may also find it difficult to recognize atypical presentations of CIDP. These issues lead to delayed diagnoses, misdiagnoses, and missed opportunities for early and timely interventions.

Join experts in the management of CIDP for a comprehensive review of the symptoms and clinical features of CIDP, along with practical and successful strategies to improve diagnosis and disease assessment. The safety, efficacy, and tolerability of available treatment options will also be explored, and strategies to address barriers to optimal management and emerging concepts in disease pathophysiology that could provide new targeted options to more effectively manage CIDP will be addressed.

Because of the significant morbidity and disease burden associated with CIDP, it is critical that clinicians and their patients be on the same page in terms of diagnosis, treatment expectations, and maintenance therapy to maximize outcomes. Direct your patients with CIDP to the associated patient activity, “Becoming Empowered with CIDP: Making My Voice Heard” at NeuroCareLive.com. Patients and their caregivers will become more familiar with both current and emerging management approaches, while recognizing their role in the treatment and monitoring process.

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship
Peter D. Donofrio, MD
Professor of Neurology
Vanderbilt University Medical Center
Consulting Fee (e.g., Advisory Board): argenx US, Inc.
Betsy Blake, PharmD, BCPS, FNAP
Clinical Associate Professor
Director of Interprofessional Education
University of South Carolina College of Pharmacy
Nothing to disclose

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Jaimee Harris-Gold Nothing to disclose
Carole Drexel Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive.com at 1-877-394-1306 or at Info@NeuroSeriesLive.com or Support@NeuroSeriesLive.com.